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ABSTRACT
International Journal of Exercise Science 9(5): 554-566, 2016. Polycystic ovary syndrome

(PCOS) may present important comorbidities, such as cardiovascular and metabolic diseases, which are
often preceded by changes in cardiac autonomic modulation. Different types of physical exercises are
frequently indicated for the prevention and treatment of PCOS. However, little is known about the effects of
strength training on the metabolic, hormonal, and cardiac autonomic parameters. Therefore, our aim was to
investigate the effects of strength training on the autonomic modulation of heart rate variability (HRV) and
its relation to endocrine-metabolic parameters in women with PCOS. Fifty-three women were divided into
two groups: CONTROL (n=26) and PCOS (n=27). The strength training lasted 4 months, which was divided
into mesocycles of 4 weeks each. The training load started with 70% of one repetition maximum (1RM).
Blood samples were collected before and after intervention for analysis of fasting insulin and glucose,
HOMA-IR, testosterone, androstenedione and testosterone/androstenedione (T/A) ratio. Spectral analysis
of HRV was performed to assess cardiac autonomic modulation indexes. The PCOS group presented higher
insulin and testosterone levels, T/A ratio, along with increased sympathetic cardiac autonomic modulation
before intervention. The training protocol used did not cause any change of endocrine-metabolic parameters
in the CONTROL group. Interestingly, in the PCOS group, reduced testosterone levels and T/A ratio.
Additionally, strength training did not have an effect on the spectral parameter values of HRV obtained in
both groups. Strength training was not able to alter HRV autonomic modulation in women with PCOS,
however may reduce testosterone levels and T/A ratio.

KEY WORDS: Heart rate variability, physical exercise
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women, with a
prevalence of up to 15% (9, 16). Although the pathophysiological mechanisms have yet to be
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totally clarified, the presence of multifactorial events related to genetic factors, body
composition, and endocrine-metabolic disorders (especially high levels of androgen) have
been observed (7, 9, 16, 19, 41). These alterations appear to promote insulin resistance and
hyperinsulinemia by modifying the mechanisms involved in the regulation of the responses of
the insulin receptors, and consequently, in glucose absorption (29, 30). In contrast, insulin
resistance seems to amplify theca steroidogenesis, an intrinsic abnormality, by stimulating the
increase of androgen synthesis (7, 41).
Additionally, the literature has shown that the excess of androgens present in women with
PCOS is a contributing factor in the development of a number of disorders, including some
cardiovascular diseases such as atherosclerosis and hypertension (4, 16). Moreover, increased
insulin resistance can lead to the development of type 2 diabetes, general and abdominal
obesity, and cardiac autonomic control damage, which may further worsen the prognosis (4, 9,
22, 34, 35, 36, 41). Therefore, studies on new therapeutic strategies should be conducted to
reduce risks in women exposed to these conditions.
The use of a structured aerobic physical exercise program has resulted in a global
improvement in cardiovascular and metabolic parameters including insulin sensitivity,
hormonal profile and cardiac autonomic balance. (10, 20, 29, 44). In contrast, strength training
is not commonly used in the treatment of PCOS. However, some studies with other
populations have shown that strength training can provide health-related benefits such as the
reduction of body fat and a decrease in the risks of hypertension and diabetes (33, 40, 44). In
this case, strength training seems to improve the insulin action/sensitivity in the muscles of
individuals with diabetes and overweight patients as well as in healthy persons (2,18). This
type of training can also promote different adaptations in hormonal profiles, including those
of the androgenic hormones (42, 43).
These findings are important because the reduction of insulin sensitivity and chronic
hyperglycemia may have negative effects on cardiac autonomic control, especially in terms of
heart rate variability (HRV), by increasing the influence of the sympathetic component and
reducing the influence of the parasympathetic component in the heart. Therefore, this
autonomic imbalance may serve as a pathway for the development and aggravation of
cardiovascular diseases (3, 30, 37). Interestingly, it was suggested that the increase of
sympathetic cardiac autonomic modulation could be related to high levels of testosterone (8),
which further emphasizes the importance of evaluating the effects of strength training in
women with PCOS.
Although the health benefits of strength training have been well recognized, scientific
evidence is still scarce, especially in women with PCOS. Therefore, in the present study was
investigated the effects of periodized strength training on cardiac autonomic parameters and
its correlation with metabolic and endocrine parameters in women with PCOS.
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METHODS
Participants
A convenience sample of 53 participants were recruited and divided into two groups: control
group (CG; N= 26) and group with the polycystic ovary syndrome (PCOS group; N= 27). The
participants were aged between 18 and 37 years, had a body mass index (BMI) between 18.0
and 39.9 kg/m2, and were not involved in any regular (two or more times a week) or
instructed physical exercises at the time of the study. For the CG, the range of the regular
menstrual cycle interval was estimated to be 22–35 days, with a duration of 3–7 days (11).
PCOS was diagnosed based on the criteria established by the Rotterdam consensus (16), and
the presence of at least two of the following criteria: menstrual irregularity (cycle length >35
days or variation between consecutive cycles of >10 days); presence of hirsutism evaluated by
a Ferriman-Gallwey score >8, severe acne and alopecia; hyperandrogenism (total testosterone
concentration >80 ng/dL); or ultrasound evidence of polycystic ovaries. All volunteers with
PCOS selected for the study had polycystic ovaries; 70.4% presented with biochemical
hyperandrogenism, 66.7% had clinical hyperandrogenism, and 88.9% had irregular menstrual
cycles. The following items were used as exclusion criteria: presence of systemic diseases and
musculoskeletal disorders that prevented the women from practicing physical exercises;
presence of congenital adrenal hyperplasia, androgen-secreting neoplasms, Cushing’s
syndrome, tabagism, and pregnancy; and use of hormonal contraceptives or drugs that
interfere with the hypothalamic-pituitary axis or cardiac autonomic modulation.
This study was conducted in accordance with the ethical standards set forth in the Helsinki
Declaration of 1975 and approved by the Human Research Ethics Committee of the Clinical
Hospital of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil (case
HCRP N. 13475/2009). The evaluations were performed before and after the physical training
period and all volunteers provided their free and informed consent.
Protocol
The strength training program lasted for 4 months, which was divided into mesocycles of 4
weeks each. The calculation of one repetition maximum (1RM) was performed for each
volunteer (32) and linear periodization was used to gradually decrease the volume and
increase the intensity during the training. The exercises included: 1) bench press, 2) leg
extension, 3) front lat pull down, 4) leg curl, 5) lateral raise, 6) leg press (45°), 5) triceps pulley,
6) calf leg press, 7) arm curl, and 8) abdominal. The training load started with 70% of 1RM, and
each exercise was repeated for 12 repetitions. In the first 3 weeks of each mesocycle, the
exercises were performed three times/week and the intensity was increased by 5% per week.
In the fourth week, these exercises were performed twice/week and the intensity were
reduced by 5% (1).
Blood samples were collected during the follicular phase, and at any time in those with
amenorrhea. The tests were performed in the Gynecology Laboratory of the HC-FMRP,
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between 07:00 and 09:00 am, after a 12-h fast. Blood (15mL) was collected into conical plastic
tubes (BD-Becton Dickinson, Plymouth, UK). The blood samples for the analysis of fasting
insulin were stored in vacuum tubes, with a separating gel barrier. The blood samples for the
other tests, except those for the analysis of fasting glucose, were stored under vacuum in tubes
containing EDTA fasting blood glucose levels was analyzed immediately after collection.
Blood was then centrifuged at 2500 rpm in a CT 5000 centrifuge (Cientec Laboratory
Equipments, São Paulo, Brazil) at room temperature (20–24°C) for 10 min and transferred to
sealed plastic tubes (Eppendorf tubes). Serum was stored at -80°C for the simultaneous
determination of all serum variables. The ELISA method was used for the analysis of sex
hormone binding globulin (SHBG). Insulin, prolactin, and thyroid stimulating hormone levels
were measured by using chemiluminescence. Glucose was measured by using the glucose
oxidase method. 17-Hydroxyprogesterone, testosterone, and androstenedione were measured
by means of radioimmunoassay. To detect insulin resistance (>2.71 nmol× µU/L), the
following equation was used: HOMA-IR (homeostatic model assessment-insulin resistance) =
[(fasting glucose in mg/dL× 0.05551) ×(fasting insulin in µU/mL/22.5)] (13, 24). The free
androgen index (FAI) was calculated by using the equation [TT (nmol/L)/SHBG (nmol/L)]×
100.
Transvaginal pelvic ultrasound was performed by using Voluson 730 Pro and Expert (GE
Medical Systems, Kretztechnik, Zipf, Austria). The ovarian volume and the number and size of
follicles (when present) were determined. The calculation of ovarian volume was performed
by using the formula for a prolate ellipsoid (15).
Body composition was determined via dual energy x-ray absorptiometry, by using the latest
program of the system (QDR Discovery Series; Hologic Inc., Waltham, MA, USA). This test
was conducted at the Science Center of Images and Medical Physics of the HC-FMRP, Brazil.
In this scanning technique, an x-ray generator emits pulses of double-energy alternate
radiation of 70 and 140 Kv (14). The photons pass through the tissues of the subject, and thus
evaluate total body fat.
Spectral analysis of HRV was performed to assess cardiac autonomic modulation. The
volunteers were requested to refrain from consuming alcoholic beverages and caffeine or from
practicing physical exercises. They were requested to maintain a regular diet in the 48 h before
the examination. The recording for spectral analysis of HRV was accomplished by using ECG
signals (AD Instruments, Sydney, Australia), between 8:00 and 11:00am, according to the
following protocol: 20 min in the supine position on a special motorized (automated) tilt table
(orthostatic table); this recording period was followed by 10 min of recording with initial
phase adaptation and 10 min of final recording in the supine position. Subsequently, the table
engine was turned on and the volunteers passively shifted from the supine position to the
orthostatic position (90°) for 10 min. The HRV analysis was performed by using custom-made
computer software (CardioSeries version 2.4; http://sites.google.com/site/cardioseries).
The RR interval (RRi) values obtained were resampled (3 Hz) by using cubic spline
interpolation to adjust the time interval between heartbeats, and were divided into segments
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with 512 values each, with 50% overlapping (Welch protocol). Each RRi stationary segment
was subjected to fast Fourier transform, after applying a Hanning window function. The
oscillatory components were classified as either low frequency (LF: 0.04–0.15 Hz) high
frequency (HF: 0.15–0.5 Hz). The mean values of the power spectral densities of RRi in both
bands (LF and HF) were expressed in absolute units (ms2). The relative power (%), also known
as normalized units (nu), in each frequency band, as well as the LF/HF ratio powers, were
calculated by subtracting the very low frequency (VLF<0.04 Hz) values. The normalization
tends to minimize the effect of changes in the total power on the values of the LF and HF
components (17, 23).
Statistical Analysis
The Shapiro-Wilk test was applied to determine the normality of the sample, with 95%
significance. The effects of PCOS and of the strength training were evaluated by using twoway ANOVA, and data are presented as means ± S.E.M. (standard error of the mean). The
comparison between groups was analyzed statistically with the Student-Newman-Keuls test,
whenever necessary. The statistical significance level was established at 5% (p < 0.05). The
associations between the percentage changes in LF/HF ratio and the endocrine-metabolic
variables were verified by using the Spearman’s rank correlation coefficient with Spearman’s
rank correlation test. For the statistical analysis and charts, Sigma Stat software (version 11.0)
was used (Systat Software Inc., San Jose, CA, USA).
RESULTS
The age and height of the women were similar in both groups: CG (31 ± 1.0 years and 1.62 ±
0.1 m) and PCOS (29 ± 1.1 years and 1.61 ± 0.1 m). Table 1 shows the values of the
hemodynamic and metabolic-endocrine parameters. No significant differences were observed
in any of the hemodynamic parameters between the CG and PCOS groups, before and after
strength training. The evaluation of endocrine-metabolic parameters showed that the PCOS
group, when compared with the CG, presented significantly higher levels of testosterone (p =
0.041) and insulin (p = 0.037) before strength training. Moreover, strength training in the CG
did not cause any significant change in the values of endocrine-metabolic parameters.
Interestingly, strength training reduced testosterone levels (p = 0.021) and T/A ratio (p =
0.004) in both groups. On the other hand, androstenedione levels remain unchanged after 4
months of training (p = 0.306).
Table 2 shows the spectral parameter values of HRV obtained in the supine and orthostatic
positions in both groups. In the supine position, there were no differences between the study
groups, and strength training did not cause any changes. However, during the tilt test, in the
orthostatic position, the PCOS group presented higher values of LF band oscillations in
absolute (p = 0.035) and normalized (p = 0.049) units and lower values of HF band oscillations
in normalized (p = 0.049) units compared with the CG. Consequently, we also observed a
higher LF/HF ratio value in the PCOS group (p = 0.047). However, strength training did not
have a significant effect on the spectral values obtained in both groups.
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Table 1. Hemodynamic and endocrine-metabolic parameters among women in the CG and PCOS groups before and after strength training.
CG (n = 26)

PCOS (n = 27)

PCOS

Strength
training

Interaction

Before

After

Before

After

F(DF)

p

F(DF)

p

F(DF)

p

Heart rate, bpm

69 ± 1.7

68 ± 1.5

66 ±1.3

67 ± 1.7

F(1,102):0.58

0.45

F(1,102):0.01

0.98

F(1,102):0.14

0.71

Systolic blood pressure, mmHg

111 ± 3

109 ± 2

115 ± 3

117 ± 4

F(1,102):62

0.13

F(1,102):1.09

1.11

F(1,102):0.72

0.77

Diastolic blood pressure, mmHg

75 ± 3

70 ± 3

77 ± 4

76 ± 4

F(1,102):45

0.24

F(1,102):0.83

0.73

F(1,102): 1.19

0.63

Mean blood pressure, mmHg

90 ± 3

86 ± 2

93 ± 4

94 ± 4

F(1,102):27

0.39

F(1,102):0.45

0.52

F(1,102):0.64

0.44

Weight, kg

70.9 ± 3.1

70.7 ± 2.9

74.4 ± 3.1

73.9 ± 3.1

F(1,102):1.36

0.246

F(1,102):0.01

0.996

F(1,102):0.01

0.949

BMI, kg/m2

26.9 ±1.1

26.9 ± 1.1

28.7 ± 1.2

28.5 ± 1.1

F(1,102):2.48

0.118

F(1,102):0.01

0.991

F(1,102):0.01

0.954

Body fat, %

38.6 ± 1.0

39.3 ± 1.1

39.8 ± 0.8

38.6 ± 0.6

F(1,102):0.12

0.724

F(1,102):0.12

0.730

F(1,102):1.11

0.294

Testosterone, ng/dL

72.6 ± 5.1

64.9 ± 2.9

87.7 ± 6.8*

71.2 ± 5.0#

F(1,102):4.29

0.041

F(1,102):5.51

0.021

F(1,102):0.71

0.400

Androstenedione, ng/dL

108.7± 6.9

108.4 ± 4.9

123.8 ± 9.0

139.3 ± 10.4+

F(1,102):7.82

0.006

F(1,102):0.85

0.360

F(1,102):0.93

0.338

T/A ratio

0.74± 0.07

0.62 ± 0.04

0.75 ± 0.05

0.55 ± 0.04#

F(1,102):0.30

0.582

F(1,102):8.77

0.004

F(1,102):0.93

0.338

SHBG

55.0 ± 5.7

46.9 ± 5.0

53.1 ± 3.9

44.96 ± 3.7

F(1,102):0.17

0.681

F(1,102):3.01

0.086

F(1,102):0.01

0.999

Hemodynamic values

Endocrine-metabolic values

FAI

169.5± 23.2

180.0 ± 22.6

197.1 ± 20.9

189.3 ± 20.7

F(1,102):0.67

0.413

F(1,102):0.01

0.933

F(1,102):0.20

0.659

Fasting glucose, mg/dL

91.6 ± 2.8

89.2 ± 2.2

92.5 ± 3.0

86.0 ± 2.5

F(1,102):0.19

0.662

F(1,102):2.82

0.096

F(1,102):0.59

0.446

Fasting insulin, µU/mL

6.22± 1.08

6.68 ± 0.98

9.60 ± 1.29*

8.85 ± 1.72

F(1,102):4.46

0.037

F(1,102):0.01

0.913

F(1,102):0.21

0.647

HOMA-IR, nmol× µU/L

1.46± 0.30

1.54 ± 0.25

2.20 ± 0.30

1.99 ± 0.44

F(1,102):3.16

0.078

F(1,102):0.04

0.841

F(1,102):0.17

0.676

All values are expressed as means ± S.E.M.CG, control group; PCOS, polycystic ovary syndrome; BMI, body mass index; SHBG, sex hormone binding
globulin; FAI, free androgen index; bpm, beats per minute; mmHg, millimeters of mercury; kg, kilograms; kg/m2, kilograms per square meter; %, percentage;
ng/dL, nanograms per deciliter; nmol/L, nanomolar per liter; mg/dLmilligrams per deciliter; µU/mL, microunits per milliliter. *p< 0.05 compared with CG
before training. # p<0.05 compared with PCOS before training. + p<0.005 compared with CG before training.
Table 2. Parameters of spectral analysis of the time series of RR intervals obtained in the supine position and during the tilt test in women from both
groups (CG and PCOS) before and after strength training.
Strength
CG (n = 26)
PCOS (n = 27)
PCOS
Interaction
training
Before
After
Before
After
F(DF)
p
F(DF)
p
F(DF)
p
Spectral analysis—supine
RRi,ms

888 ± 23

886 ± 24

906 ± 18

903 ± 22

F(1,102):0.67

0.414

F(1,102):0.01

0.917

F(1,102):0.01

0.987

Variance, ms2

2663 ± 597

2914 ± 692

2881 ± 492

2314 ± 304

F(1,102):0.13

0.723

F(1,102):0.09

0.768

F(1,102):0.58

0.477

LF, ms2

829 ± 223

704 ±137

871 ± 242

591 ± 81

F(1,102):0.04

0.846

F(1,102):1.23

0.271

F(1,102):0.18

0.673

HF, ms2

1165 ± 310

1473 ± 507

1138 ± 243

987 ±190

F(1,102):0.60

0.440

F(1,102):0.06

0.813

F(1,102):0.48

0.491

LF, nu

43 ± 3

41± 4

43 ± 3

42± 3

F(1,102):0.01

0.924

F(1,102):0.23

0.632

F(1,102):0.07

0.797

HF, nu

57 ± 3

59 ± 4

57± 3

58 ± 3

F(1,102):0.01

0.924

F(1,102):0.23

0.632

F(1,102):0.07

0.797

0.90 ± 0.11

0.89 ± 0.13

0.93 ± 0.15

0.90 ± 0.13

F(1,102):0.02

0.891

F(1,102):0.03

0.868

F(1,102):0.01

0.914

LF/HF ratio
Spectral analysis—tilt test
RRi, ms

708 ±19

699 ±16

724 ±15

711 ±16

F(1,102):0.72

0.397

F(1,102):0.37

0.542

F(1,102):0.01

0.894

1571 ± 242

1541 ± 212

1940 ± 256

1927 ± 241

F(1,102):2.48

0.118

F(1,102):0.01

0.929

F(1,102):0.01

0.973

LF, ms2

584 ± 84

568 ± 77

830 ± 123*

821 ±159

F(1,102):4.57

0.035

F(1,102):0.01

0.912

F(1,102):0.01

0.974

HF, ms2

329 ±131

246 ±71

258 ± 70

200 ± 41

F(1,102):0.47

0.493

F(1,102):0.70

0.403

F(1,102):0.02

0.881

LF,nu

71 ± 3

74 ± 3

78 ± 2*

79 ± 2

F(1,102):3.96

0.049

F(1,102):0.62

0.431

F(1,102):0.16

0.694

HF,nu

29 ±3

26 ± 3

22 ± 2*

21 ± 3

F(1,102):3.96

0.049

F(1,102):0.62

0.431

F(1,102):0.16

0.694

3.99 ± 0.62

4.32 ± 0.60

5.21 ± 0.77*

6.12 ± 0.96

F(1,102):4.02

0.047

F(1,102):0.69

0.416

F(1,102):0.15

0.701

Variance, ms2

LF/HF ratio

All values are expressed as means ± S.E.M. CG, control group; PCOS, polycystic ovary syndrome; RRi, RR interval; LF, low frequency; HF, high frequency;
ms, millisecond; ms2, millisecond squared; nu, normalized unit.*p<0.05 compared with CG before training.

Figures 1 and 2 present the results of the spectral analysis of HRV in the CG and PCOS groups,
by comparing the values of the total variance (including LF and HF bands in absolute and
normalized units) obtained in the supine and orthostatic positions (tilt test) before and after
strength training. The results obtained during the tilt test in the CG (Figure 1) showed
significant reductions in total variance, in the LF band in normalized units, and in the HF band
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in absolute and normalized units, which significantly increased the LF/HF ratio. Strength
training did not change the observed responses. The PCOS group (Figure 2) showed similar
results to those seen in the CG, with the exception of the total variance, which did not differ in
the transition from supine position to orthostatic position during the tilt test.

Figure 1. Parameters of spectral analysis of the time
series of RR intervals (RRi) obtained in the supine
position and during the tilt test in women from the
control group (CG) before and after strength training.
All values are expressed as means ± S.E.M. *p<0.05
compared with the CG in the supine position. HF,
high frequency; LF, low frequency; nu, normalized
units.

Figure 2. Parameters of spectral analysis of the time
series of RR intervals (RRi) obtained in supine
position and during the tilt test of women in the
polycystic ovary syndrome (PCOS) group before and
after the physical strength training. All values are
expressed as means ± S.E.M.*p<0.05 compared with
the PCOS group in the supine position. HF, high
frequency; LF, low frequency; nu, normalized units.

Table 3 shows the correlation values between the percentage variations of the LF/HF ratio and
the values of the percentage variation of the endocrine-metabolic parameters in the CG and
PCOS group, in the supine position and during the tilt test. There was no correlation with any
of the variables in both groups in the supine position and during the tilt test for the CG.
However, during the tilt test, the PCOS group showed a negative correlation between the
percentage variation of the LF/HF ratio and the percentage variation of androstenedione
values (p = 0.014), as well as a positive correlation between the percentage variation of the
LF/HF ratio and the percentage variation of T/A ratio (p < 0.001).
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Table 3. Correlation values between the percentage variations of the LF/HF ratio and the values of the percentage variation of the endocrine-metabolic
parameters in the CG and PCOS groups obtained in the supine and orthostatic positions.
CG (n = 26)

Endocrine-metabolic values

PCOS (n = 27)

CG (n = 26)

PCOS (n = 27)

Supine

Tilt test

LF/HF

LF/HF

r

p

R

p

r

p

r

p

Weight, kg

0.314

0.117

0.006

0.973

0.056

0.784

-0.282

0.161

BMI, kg/m2

0.314

0.117

0.006

0.973

0.056

0.784

-0.282

0.161

Body fat, %

0.292

0.146

-0.009

0.963

0.200

0.324

0.153

0.452

Testosterone, ng/dL

0.113

0.578

-0.032

0.873

0.129

0.526

0.088

0.666

Androstenedione, ng/dL

0.081

0.668

-0.289

0.150

-0.255

0.205

-0.476

0.014

T/A ratio

-0.063

0.756

0.378

0.056

0.305

0.129

0.615

<0.001

SHBG

0.147

0.471

-0.07

0.728

0.272

0.176

0.176

0.386

FAI

-0.069

0.733

0.057

0.779

-0.024

0.904

0.028

0.891

Fasting glucose, mg/dL

-0.159

0.434

0.194

0.339

-0.070

0.731

-0.299

0.136

Fasting insulin, µU/mL

0.307

0.126

-0.077

0.703

0.298

0.138

-0.318

0.112

HOMA-IR, nmol× µU/L

0.344

0.084

-0.012

0.952

0.363

0.068

-0.342

0.087

CG, control group; PCOS, polycystic ovary syndrome; BMI, body mass index; T/A, testosterone/androstenedione; SHBG, sex hormone binding globulin; FAI,
free androgen index; bpm, beats per minute; mmHg, millimeters of mercury; kg,kilograms; kg/m2, kilograms per square meter; %, percentage; ng/dL,
nanograms per deciliter; nmol/L, nanomolar per liter; mg/dLmilligrams per deciliter; µU/mL, microunits per liter. *p< 0.05.

DISCUSSION
The two main findings of the present study are that women with PCOS presented higher
sympathetic cardiac autonomic modulation during the tilt test and higher levels of
Testosterone and T/A levels. In addition, strength training was able to reduce testosterone
levels and the T/A ratio, however, did not affect cardiac autonomic modulation.
Damage to the cardiac autonomic imbalance is commonly associated with cardio metabolic
disorders such as diabetes, hypertension, and metabolic syndrome. Augmented sympathetic
tone and reduced HRV are correlated with factors such as increased insulin resistance,
hyperandrogenism, increased BMI, vascular alterations, and inflammatory processes (3, 6, 30,
34, 36). In women with PCOS, the risks are even higher because these factors contribute to a
vicious cycle that increases androgen production and adipogenesis (7, 41). At the same time,
the excess of androgens in women stimulates and promotes an increase in insulin resistance
(19, 21, 28, 29).
In our study, the cardiac autonomic modulation assessed by the analysis of HRV in the supine
position showed that the two groups had similar behavior, thus corroborating the findings of a
recent study (6). However, other studies have reported an increase in the modulation of the
sympathetic component in the supine position (34, 45), whereas other authors have reported a
reduced HRV in these women (5, 34, 39). In contrast, during the tilt test, both groups showed
an increased LF band in normalized units and reduced HF band in absolute and normalized
units in the orthostatic position, thus increasing the LF/HF ratio. However, the two groups
showed different results in total variance; that is, only the CG showed a significant reduction
during the tilt test, both before and after strength training.
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Generally, the change of position during the tilt test causes a reduction in the total variance of
the spectrum due to the reduction of oscillatory components, which are greater in the supine
position and are attributable mainly to the influences of oscillation on the vagal activity
present in the HF band (17, 23). The explanation for the no reduction of the total variance in
women with PCOS is that, unlike the CG, when the tilt test is applied in the PCOS group, there
is greater response in the LF band, with a maintenance tendency or an increase of the LF
oscillations in absolute units (ms2). One of the possible reasons for this finding seems to be
related to the increased levels of androgens and insulin (27, 31, 38). In another study, it was
demonstrated that men exhibit greater sympathetic modulation than women, probably owing
to several factors, including the high serum levels of androgens (8).
In present study, a positive correlation was observed between the LF/HF ratio and the T/A
ratio, and a negative relation between the LF/HF ratio and androstenedione. The explanation
for such an outcome has not been completely established. However, it is known that a number
of factors, including hyperinsulinemia, can lead to an increased secretion of androgens such as
androstenedione (7, 25, 28, 29, 31). Thus, androstenedione is then converted into higher
testosterone levels, which seem to establish a positive feedback with increased body fat
percentage, thus increasing the insulin and testosterone levels and reinforcing the increased
insulin resistance (7, 25, 26, 29). However, the reduction on testosterone and T/A ratio levels in
the PCOS group after strength training did not cause any changes in the cardiac autonomic
modulation, both in the supine and orthostatic positions after the tilt test. These results
revealed that other factors may have contributed to the modification of HRV after strength
training. One of these factors is the high serum insulin concentrations observed in women of
the PCOS group (3, 17, 37), as the literature has shown that high concentrations of insulin have
a strong correlation with an increase in visceral fat. In this case, even lean women with PCOS,
but with increased visceral fat, would have a greater likelihood of presenting insulin resistance
(4, 21, 22). In the present study, women with and without PCOS had similar BMI values and
body fat percentages, both before and after strength training. These women were considered to
be overweight, and in a few cases, were classified as grade I overweight (12). However, the fact
that visceral fat was not quantified in our study is a limiting factor for attributing the effects
observed in the HRV to this type of fat, even though the literature has shown that its increase
can substantially change the cardiovascular and endocrine-metabolic parameters (4, 21, 22).
In contrast to results, some studies on strength training found a reduction of hyperinsulinemia,
which can be explained by some mechanisms that contribute to increasing GLUT4
translocation to the cell surface (2,18). However, studies on the effects of strength training on
cardiac autonomic modulation and on hyperinsulinemia are scarce, unlike aerobic training
that already has well-established benefits (10, 20, 29, 44).
On the basis of the results obtained, it can be concluded that strength training is satisfactory
and relevant in women with PCOS. However, it is suggested the combination with aerobic
physical training and dietary intake control to enhance the effects on the metabolism and on
the reduction of body fat, thus reducing the risks of cardiovascular and metabolic diseases.
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Lastly, the results suggest that strength training was not able to alter HRV autonomic
modulation in women with PCOS, however, may reduce testosterone levels and T/A ratio.
The study showed that strength training should be prescribed in the treatment of women with
PCOS, as it promotes the improvement of some parameters evaluated, especially related to the
androgenic hormonal profile. Future studies should be designed to identify the insulin
relationship with the cardiac autonomic control and the role of strength training in other
respects, such as its effect on visceral fat and other markers as adipokines and stress oxidative.
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